TriSalus Life Sciences In...

NASDAQ: TLSI · Real-Time Price · USD
5.48
0.14 (2.62%)
At close: Jun 06, 2025, 3:59 PM
5.32
-2.92%
After-hours: Jun 06, 2025, 04:57 PM EDT

Company Description

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors.

The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors.

It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers.

The company is based in Westminster, Colorado.

TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc. logo
Country United States
IPO Date Feb 8, 2021
Industry Medical - Devices
Sector Healthcare
Employees 110
CEO Mary T. Szela B.S.N., M.B.A.

Contact Details

Address:
6272 West 91st Avenue
Westminster, Colorado
United States
Website https://trisaluslifesci.com

Stock Details

Ticker Symbol TLSI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001826667
CUSIP Number 89680M101
ISIN Number US89680M1018
Employer ID 85-3009869
SIC Code 6770

Key Executives

Name Position
Mary T. Szela B.S.N., M.B.A. Chief Executive Officer, President & Director
James E. Young Chief Financial Officer, Secretary & Treasurer
Dr. Bryan F. Cox Ph.D. Chief of Research
Dr. Richard B. Marshak M.B.A., MBA, VMD Chief Commercial Officer
Jennifer L. Stevens J.D. Chief Regulatory Officer
Jodi Devlin Chief of Clinical Strategy & Operations
Lori Ann Santamaria Vice President of Operations

Latest SEC Filings

Date Type Title
May 30, 2025 S-3 Filing
May 30, 2025 8-K Current Report
May 30, 2025 10-K/A [Amend] Annual Report
May 21, 2025 4 Filing
May 21, 2025 4 Filing
May 21, 2025 4 Filing
May 21, 2025 4 Filing
May 21, 2025 4 Filing
May 21, 2025 4 Filing
May 15, 2025 10-Q Quarterly Report